Veralox Therapeutics
- Biotech or pharma, therapeutic R&D
VERALOX is focused on the discovery and development of innovative small molecules to treat serious immuno-inflammatory disease. Our lead product, VLX-1005, is a first-in-class 12-lipoxygenase inhibitor (12-LOX) NCE with fast track and ODD designation (FDA & EMA) for treatment of Heparin Induced Thrombocytopenia (HIT). PoC data are expected by 2Q 2025.
We also are developing a series of unique cGAS inhibitors well differentiated from competitive programs with the ability to be best in class. These are currently in preclinical development.
NO SERVICE PROVIDERS PLEASE.
www.veralox.com
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}